Amgen exits brodalumab collaboration with AZ

Amgen Inc. (NASDAQ:AMGN) said it is withdrawing from a collaboration with AstraZeneca plc (LSE:AZN; NYSE:AZN) to develop and commercialize brodalumab because Amgen is concerned the compound will require restrictive labeling based on suicidal ideation and behavior seen in clinical trials.

Amgen spokesperson Trish Hawkins told BioCentury there have been "suicides in the single digits across the entire brodalumab program involving more than 5,000 patients." ...